r.mcalister
TL3 Regular · Glasgow, UK
Retired process engineer. Interested in variability: between batches, between people, between weeks.
Joined 30 September 2024 · last posted 6d
132Posts here
1Topics
1Solutions
905Likes received
490Likes given
23Badges
199Days visited
2.9kPosts read
Stated areas
Recent activity
Full stream-
Common supplements people ask about, assessed one at a time Replied, post #83 · Practice › Interactions · 22 Jul 2026 · 0 likes SGLT2 inhibitors: frequently co-administered and relevant to renal and cardiovascular discussion, not to interactions. There is no pharmacokinetic interaction of concern.
-
[2026 update] Detection wavelength and why 214 nm and 280 nm disagree Replied, post #59 · Analytics › HPLC & UHPLC · 22 Jul 2026 · 1 like This follows post #56 rather than contradicting it. Before anything else: what was the gradient, and at what wavelength? Area percent at different wavelengths is not…
-
Seven-day rolling means and why weekly readings mislead Replied, post #82 · Outcomes › Progress reports · 22 Jul 2026 · 2 likes This follows post #79 rather than contradicting it. Protein intake and resistance training: both self-reported and therefore optimistic in most reports. Recording them…
-
PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one Replied, post #14 · Compounds › Oral incretins · 21 Jul 2026 · 8 likes On post #10 — agreed on the reasoning, with one qualification. Why an oral formulation is a formulation achievement: the molecule is the same but the tablet is novel.…
-
Seven-day rolling means and why weekly readings mislead Replied, post #61 · Outcomes › Progress reports · 19 Jul 2026 · 21 likes On post #57 — agreed on the reasoning, with one qualification. Measurement noise: day-to-day body mass varies by more than a kilogram on hydration, glycogen, and gut…
-
Prior authorisation: what the criteria usually require — a second dataset Replied, post #41 · Access › Insurance & coverage · 18 Jul 2026 · 19 likes Out-of-pocket costs: if insurance is not covering it, asking about patient assistance programmes run by manufacturers can reduce costs. Eligibility requirements exist…
-
Revisiting: PCOS and metabolic overlap: what is and is not studied Replied, post #54 · Clinical › Comorbidities · 13 Jul 2026 · 3 likes On post #50 — agreed on the reasoning, with one qualification. Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly…
-
How to ask a question when you cannot say why you are asking it Replied, post #32 · Start Here › How to Ask · 6 Jul 2026 · 30 likes Avoid "any advice?" at the end. It is so generic that people do not know which part of the post it refers to. Pick the specific part and ask that specific question…
-
Reading a rodent study on a secretagogue without over-extrapolating — the long version Replied, post #19 · Compounds › Secretagogues & GH axis · 2 Jul 2026 · 30 likes This follows post #16 rather than contradicting it. Secretagogues and glucose tolerance: there is a mechanistic concern that sustained growth hormone elevation might…
-
Packaging that arrived damaged: documenting it properly Replied, post #34 · Sourcing › Logistics · 1 Jul 2026 · 31 likes At what point is a parcel genuinely a problem: if it was despatched weeks ago and there has been no update for days at customs, it might be held or lost. Days of delay…
-
Pages past their review date, listed — does this still hold? Replied, post #24 · Meta › Wiki maintenance · 24 Jun 2026 · 1 like Evidence synthesis: if you think a page should cover recent evidence or a new development, suggesting specific content helps the maintainer prioritise updates.
-
Does dual agonism explain the effect size, or is it dose? Replied, post #36 · Compounds › Tirzepatide · 14 Jun 2026 · 31 likes SURPASS-2 compared tirzepatide with semaglutide 1.0 mg, the licensed diabetes dose at that time. It did not compare with semaglutide 2.4 mg, the highest approved dose.…